Navigation Links
Isis Reports Financial Results and Highlights for Second Quarter of 2008
Date:8/7/2008

- Isis ends the second quarter with more than $535 million in cash

- Conference Call Webcast Thursday, August 7, 8:30 a.m. EDT at

http://www.isispharm.com

CARLSBAD, Calif., Aug. 7 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its financial results for the second quarter ended June 30, 2008. The Company ended the quarter in the strongest financial position in its history with more than $535 million of cash and $873,000 of pro forma operating income in the second quarter.

"Over the last year we have added significant cash through our recent collaborations. More importantly, as our corporate alliances continue to be successful, we will continue to add cash to our balance sheet and revenue to our P&L. We remain on track to end 2008 with more than $450 million in cash and to meet our pro forma net operating loss guidance of less than $15 million for the year," commented B. Lynne Parshall, COO and CFO of Isis.

"Our strong financial position is a result of the successful execution of our business strategy, enabled by the efficiency of our antisense technology. The transactions we have completed balance both our short-term and long-term objectives. In addition, the maturation of our satellite companies is providing exactly the types of financial benefits for which they were created," continued Ms. Parshall. "Because of our partnering successes, we have reported our second profitable quarter in the past year. While we are not yet at the point of sustainable profitability and our quarter-to-quarter performance will continue to fluctuate based on one-time events such as the Teva-ATL license fee, our si requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals is a registered trademark of Isis Pharmaceuticals, Inc. Ibis Biosciences and Ibis T5000 are trademarks of Ibis Biosciences, Inc. Regulus Therapeutics is a trademark of Regulus Therapeutics LLC.

ISIS PHARMACEUTICALS, INC.

SELECTED FINANCIAL INFORMATION

Condensed Consolidated Statements of Operations

(In Thousands, Except Per Share Data)

Three months ended, Six months ended,

June 30, June 30,

2008 2007 2008 2007

Revenue: (unaudited) (unaudited)

Research and development revenue

under collaborative agreements $26,814 $3,482 $47,499 $5,484

Licensing and royalty revenue 6,147 331 6,815 779

Total revenue 32,961 3,813 54,314 6,263

Expenses:

Research and development 31,195 20,384 57,642 40,333

Selling, general and

administrative 4,899 3,089 8,635 6,491

Total operating expenses 36,094 23,473 66,277 46,824

Loss from operations (3,133) (19,660) (11,963) (40,561)

Other income (expense):

Investment income 560 3,053 5,515 6,454

Interest expense (1,391) (2,016) (2,788) (4,644)

Gain on investments, net - 1,989 - 3,510

Loss on early retirement of debt - (1,993) - (3,212)

Loss attributed to noncontrolling

interest in Symphony GenIsis, Inc. - 7,603 - 14,409

Loss attributed to noncontrolling

interest in Regulus Therapeutics LLC 965 - 1,848 -

Loss attributed to noncontrolling

interest in Ibis Biosciences, Inc. 791 - 896 -

Net loss applicable to common stock $(2,208) $(11,024) $(6,492) $(24,044)

Basic and diluted net loss per share $(0.02) $(0.13) $(0.07) $(0.29)

Shares used in computing basic and

diluted net loss per share 94,675 82,548 92,737 82,502

Isis Pharmaceuticals, Inc.

Reconciliation of GAAP to Pro Forma Basis:

Condensed Consolidated Operating Expenses and Loss From Operations

(In Thousands)

Three months ended, Six months ended,

June 30, June 30,

2008 2007 2008 2007

(unaudited) (unaudited)

As reported operating expenses

according to GAAP $36,094 $23,473 $66,277 $46,824

Excluding compensation

expense related to stock

options pursuant to SFAS 123(R) (4,006) (2,389) (7,765) (4,753)

Pro forma operating expenses $32,088 $21,084 $58,512 $42,071

As reported loss from operations

according to GAAP $(3,133) $(19,660) $(11,963) $(40,561)

Excluding compensation

expense related to stock

options pursuant to SFAS 123(R) (4,006) (2,389) (7,765) (4,753)

Pro forma income (loss) from

operations $873 $(17,271) $(4,198) $(35,808)

Reconciliation of GAAP to Pro Forma Basis

As illustrated in the Selected Financial Information in this press release, pro forma operating expenses and pro forma income (loss) from operations were adjusted from GAAP to exclude compensation expense related to stock options, which are non-cash. Isis has regularly reported non-GAAP measures for operating expenses and loss from operations as pro forma results. These measures are provided as supplementary information and are not a substitute for financial measures calculated in accordance with GAAP. Isis reports these pro forma results to better enable financial statement users to assess and compare its historical performance and project its future operating results and cash flows. Further, the presentation of Isis' pro forma results is consistent with how Isis' management internally evaluates the performance of its operations.

Ibis Biosciences, Inc.

Statements of Operations

(In Thousands)

Three months ended, Six months ended,

June 30, June 30,

2008 2007 2008 2007

(unaudited) (unaudited)

Revenue:

Commercial revenue(1) $1,098 $810 $2,293 $1,441

Research and development

revenue under collaborative

agreements 2,160 1,081 3,944 2,026

Total revenue 3,258 1,891 6,237 3,467

Expenses:

Cost of commercial revenue(2) 3,078 1,266 3,895 2,801

Research and development 3,572 2,460 8,128 4,647

Selling, general and

administrative 2,024 1,035 3,527 2,023

Total operating expenses 8,674 4,761 15,550 9,471

Loss from operations $(5,416) $(2,870) $(9,313) $(6,004)

(1) Ibis' commercial revenue has been classified as research and

development revenue under collaborative agreements on Isis' condensed

consolidated statement of operations.

(2) Ibis' cost of commercial revenue has been classified as research and

development expenses on Isis' condensed consolidated statement of

operations.

Regulus Therapeutics LLC

Statements of Operations

(In Thousands)

Three Months Six Months

Ended Ended

June 30, 2008 June 30, 2008

Revenue:

Research and development revenue under

collaborative agreements $656 $748

Total revenue 656 748

Expenses:

Research and development 1,606 2,918

General and administrative 917 1,132

Total operating expenses 2,523 4,050

Loss from operations $(1,867) $(3,302)

Regulus was formed in the third quarter of 2007; therefore it does not have operating results for the first half of 2007.

Isis Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(In Thousands)

June 30, December 31,

2008 2007

(unaudited)

Assets:

Cash, cash equivalents and short-term

investments $536,969 $193,719

Other current assets 18,211 13,598

Property, plant and equipment, net 10,494 7,131

Other assets 43,725 44,410

Total assets $609,399 $258,858

Liabilities, noncontrolling interest and

stockholders' equity:

Other current liabilities $25,604 $29,000

Current portion of deferred contract revenue 101,507 33,205

2 5/8% convertible subordinated notes 162,500 162,500

Long-term obligations, less current portion 5,415 362

Long-term deferred contract revenue 214,202 23,548

Noncontrolling interest in Regulus

Therapeutics LLC 7,523 9,371

Noncontrolling interest in Ibis Biosciences, Inc. 33,625 -

Stockholders' equity 59,023 872

Total liabilities, noncontrolling interest

and stockholders' equity $609,399 $258,858

gnificant continuing revenue base coupled to our business model supports expansion of our pipeline while controlling our expenses, which we believe will lead to continuing strong financial performance."

Upcoming Key Milestones

-- Initiate three trials in addition to the Phase 3 study in patients

with heterozygous Familial Hypercholesterolemia (FH) announced this

week, studying mipomersen in apheresis-eligible patients and high-risk

high cholesterol patients

-- Present liver imaging safety data on mipomersen

-- Initiate Phase 1 clinical study on ISIS 353512, Isis' drug targeting

CRP for the treatment of cardiovascular, renal and inflammatory

diseases

-- Report Phase 2 study data in type 2 diabetics treated with ISIS 113715

and sulfonylureas

-- Complete Phase 1 study with ISIS 325568, targeting GCGR for the

treatment of type 2 diabetes

-- Initiate Phase 1 study on ISIS 333611, Isis' first CNS drug targeting

SOD1 for the treatment of ALS

-- Advance a second new drug candidate into development

-- Potential acquisition of Ibis by Abbott

Financial Results

Isis had $873,000 of pro forma profit from operations in the second quarter of 2008 and a pro forma net operating loss (NOL) for the six months ended June 30, 2008 of $4.2 million, excluding compensation expense related to stock options, compared to an NOL of $17.3 million and $35.8 million during the same periods in 2007. On a GAAP basis, Isis recorded a loss from operations for the three and six months ended June 30, 2008 of $3.1 million and $12.0 million, respectively, compared to $19.7 million and $40.6 million for the same periods in 2007. The significant improvement in the Company's pro forma and GAAP operating results was driven primarily by the significant increase in revenue in 2008 from Isis' corporate partnerships. This was offset, in part, by higher expenses associated with the expansion of the companies' programs and, for Isis' GAAP results, an increase in non-cash stock compensation expense reflecting the increase in Isis' stock price over the same periods. The reconciliation of pro forma and GAAP measures is explained later in this release.

Revenue

Total revenue for the three and six months ended June 30, 2008 of $33.0 million and $54.3 million, respectively, was significantly higher than the revenue from the same periods in 2007 of $3.8 million and $6.3 million as a result of Isis' new collaborations. As part of Isis' strategic relationship with Genzyme Corporation, in the first quarter of 2008 Genzyme purchased $150 million of Isis stock at $30 per share and in the second quarter paid Isis a licensing fee of $175 million. Isis is amortizing the premium on the stock and the license fee into revenue through June 2012. Additionally, in the second quarter of 2008, Isis continued to recognize significant value from its partnerships, satellite companies and subsidiaries including:
-- $2.0 million milestone payment from Bristol-Myers Squibb for a PCSK9

development candidate

-- $4.6 million from Alnylam Pharmaceuticals, Inc.

-- $1.4 million from Antisense Therapeutics Limited

-- $3.3 million from Ibis representing a 72% increase from second half of

2007

-- $656,000 of revenue from Regulus primarily from its GlaxoSmithKline

(GSK) alliance

Operating Expenses

On a pro forma basis, operating expenses for the three and six months ended June 30, 2008 were $32.1 million and $58.5 million, respectively, compared to $21.1 million and $42.1 million for the same periods in 2007. The increase in operating expenses year over year is due to Isis' expanded clinical development programs as its drugs advance in development, an increase in Ibis' operating expenses to support the growth of its commercial business and the activities to achieve the Abbott milestones, and expenses for Regulus, which began in September 2007. On a GAAP basis, Isis' operating expenses for the three and six months ended June 30, 2008 were $36.1 million and $66.3 million, respectively, compared to $23.5 million and $46.8 million for the same periods in 2007, including non-cash compensation expense related to stock options of $4.0 million and $7.8 million for the three and six months ended June 30, 2008 and $2.4 million and $4.8 million for the same periods in 2007.

Net Loss

Isis' net loss for the three and six months ended June 30, 2008 was $2.2 million and $6.5 million, respectively, compared to $11.0 million and $24.0 million for the same periods in 2007. Isis' net loss for the first half of 2008 was lower than the first half of 2007 primarily due to the decrease in the Company's loss from operations.

Balance Sheet

As of June 30, 2008, Isis had cash, cash equivalents and short-term investments of $537.0 million compared to $193.7 million at December 31, 2007. In 2008, Isis has received a significant amount of cash from its partners including:
-- $325.0 million from Genzyme

-- $40.5 million from Abbott

-- $20.0 million from GSK

As of June 30, 2008, Isis had consolidated working capital of $428.1 million compared to $145.1 million at December 31, 2007. The cash Isis received in the first half of 2008 primarily led to the increase in Isis' consolidated working capital, offset by $68.9 million of deferred revenue from Genzyme and GSK that is included in current liabilities.

Based on Isis' existing and committed cash, not including the cash Isis could receive from Abbott if Abbott completes its purchase of Ibis, Isis remains on track to meet its cash guidance with a 2008 year end cash balance greater than $450 million, which the Company expects will last for at least five years.

Ibis Biosciences, Inc.

Ibis' revenue for the three and six months ended June 30, 2008 was $3.3 million and $6.2 million, respectively, compared to $1.9 million and $3.5 million for the same periods in 2007. Ibis' commercial revenue of $1.1 million and $2.3 million for the three and six months ended June 30, 2008 consisted of revenue from sales of Ibis T5000(TM) Biosensor Systems and assay kits, as well as revenue from Ibis' assay services business. In addition, Ibis' commercial revenue included revenue from the distribution agreement Ibis and Abbott entered into in March 2008. Ibis' revenue from government contracts was $2.2 million and $3.9 million for the three and six months ended June 30, 2008, and was driven primarily by contracts awarded in late 2007 and 2008 to date. Ibis was awarded $3.2 million of new contracts in the first half of 2008 that support Ibis' continued revenue growth by expanding the applications for the T5000 Biosensor System.

Excluding non-cash compensation expense related to stock options, operating expenses for Ibis were $8.2 million and $14.6 million for the three and six months ended June 30, 2008, compared to $4.4 million and $8.7 million for the same periods in 2007. The increase in operating expenses primarily reflects an increase in costs to support the growth of Ibis' commercial business and the cost to achieve milestones as part of the Abbott transaction. Ibis generated a loss from operations, excluding non-cash compensation expense related to stock options, of $5.0 million and $8.4 million for the three and six months ended June 30, 2008, compared to $2.5 million and $5.2 million for the same periods in 2007. Ibis' non-cash compensation expense related to stock options was $466,000 and $942,000 for the three and six months ended June 30, 2008, compared to $406,000 and $815,000 for the same periods in 2007.

Regulus Therapeutics LLC

Regulus' revenue for the three and six months ended June 30, 2008 was $656,000 and $748,000 related primarily to revenue from its recently completed collaboration with GSK. As part of Regulus' strategic alliance with GSK, Regulus received a $15 million upfront fee, which it began amortizing into revenue in the second quarter of 2008 and will continue to amortize over its six-year period of performance under the agreement.

Excluding non-cash compensation expense related to stock options, operating expenses for Regulus were $1.8 million and $3.0 million for the three and six months ended June 30, 2008. With the recently announced strategic alliance with GSK, it is anticipated that Regulus' expenses will increase as Regulus continues to advance its research and development activities. The GSK alliance enhances Regulus' ability to expand operations and advance its programs. Regulus generated a loss from operations, excluding non-cash compensation expense related to stock options, of $1.2 million and $2.2 million for the three and six months ended June 30, 2008. Regulus' non-cash compensation expense related to stock options was $681,000 and $1.1 million for the three and six months ended June 30, 2008. Because Regulus was formed in the third quarter of 2007, it did not have operating results in the first half of 2007.

Quarterly Highlights

"Since the completion of our Genzyme collaboration, we've made great progress with mipomersen by initiating the first of four studies scheduled to begin by year end and receiving a patent allowance that gives the Isis-Genzyme Apolipoprotein B franchise broad protection of mipomersen and other antisense apoB compounds. In addition to the successes of our partnered drugs and satellite companies in the first half of the year, we continue to maximize the economic potential of our business model and our technology, while enabling the advancement of a broad portfolio of both partnered and internally developed drugs," concluded Ms. Parshall.

Cardiovascular Program

-- Completed licensing transaction for mipomersen

-- Finalized and announced 2008 mipomersen development plan with Genzyme

-- Reported preclinical study in Circulation showing that mipomersen

lowers Lp(a) and oxidized-LDL, independent risk factors for

cardiovascular disease

-- Initiated Phase 3 study in heterozygous FH subjects with coronary

artery disease

-- Granted broad patent coverage for antisense compounds targeting

apolipoprotein B, U.S. Patent No. 7,407,943 entitled "Antisense

modulation of Apolipoprotein B Expression"

Metabolic Program

-- Highlighted our robust diabetes and obesity portfolio with nine

presentations and posters at the American Diabetes Association meeting

-- Presented new preclinical data relating to ISIS 388626, Isis' drug

targeting SGLT2

-- Presented results from eight research programs on novel targets

that offer new mechanisms to address metabolic diseases, including

obesity

Other Partnered Programs

-- ATL and Teva reported encouraging Phase 2 results for ATL/TV1102,

targeting VLA-4 in patients with multiple sclerosis

-- Partnered oncology drugs highlighted at the American Society of

Clinical Oncology demonstrate the potential of antisense technology to

treat multiple cancers

-- OncoGenex reported encouraging Phase 2 results on OGX-011,

targeting clusterin, in patients with hormone refractory prostate

cancer

-- Eli Lilly and Company reported positive Phase 1 clinical trial

results for LY2181308, targeting survivin

-- Atlantic Healthcare received U.S. orphan drug designation for

alicaforsen for the treatment of pouchitis

-- Altair Therapeutics advanced AIR 645 into Phase 1 studies for the

treatment of asthma

Regulus Therapeutics (microRNA Joint Venture)

-- Entered into strategic alliance with GlaxoSmithKline

-- Obtained exclusive rights from Stanford University to worldwide patent

applications covering methods and compositions for antagonizing

miR-181a

-- Selected as one of the FierceBiotech's 'Fierce 15' for 2008

Ibis Biosciences

-- Received an additional $20 million investment from Abbott for a total

of 18.6 percent equity in Ibis, retaining Abbott's exclusive option to

purchase remaining equity by June 30, 2009

-- Extended government contracts that add to Ibis' revenue and fund the

expansion of applications of the Ibis T5000 technology

Conference Call

At 8:30 a.m. Eastern Time today, August 7, Isis will conduct a live webcast conference call to discuss this earnings release and related activities. Interested parties may access the webcast at http://www.isispharm.com or listen to the call by dialing 877-627-6585. A webcast replay will be available for a limited time at the same address.

About Isis Pharmaceuticals, Inc.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 18 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Ibis Biosciences, Inc., Isis' majority-owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. Isis is a joint owner of Regulus Therapeutics LLC, a joint venture focused on the discovery, development and commercialization of microRNA therapeutics. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at http://www.isispharm.com.

This press release includes forward-looking statements regarding Isis Pharmaceuticals' business, the financial position and outlook for Isis as well as its Ibis Biosciences subsidiary and its Regulus joint venture, and the therapeutic and commercial potential of the Company's technologies and products in development. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals or projections. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, in developing and commercializing systems to identify infectious organisms that are effective and commercially attractive, and in the endeavor of building a business around such products. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward- looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2007, and its quarterly report on Form 10-Q for the quarter ended March 31, 2008, which are on file with the SEC. Copies of these and other documents are available from the Company.

In this press release, unless the context
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Barr Reports Second Quarter 2008 GAAP Earnings of $0.52 Per Share; Adjusted Earnings of $0.64 Per Share
2. PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
3. Caliper Life Sciences Reports Second Quarter 2008 Results
4. Watson Pharmaceuticals Reports Second Quarter 2008 Results
5. EntreMed Reports Second Quarter 2008 Financial Results
6. Transgenomic Reports Second Quarter 2008 Results
7. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
8. Bionovo Reports Second Quarter 2008 Financial Results
9. AtriCure Reports Record Second Quarter 2008 Financial Results
10. AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008
11. eResearchTechnology Reports Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... ... to delivering cutting-edge information focused on the development and manufacture of biopharmaceuticals ... a premier sponsor of the 2016 BioProcess International Awards – Recognizing Excellence ...
(Date:2/11/2016)... ... 2016 , ... Global Stem Cells Group, a ... Stem Cells Network (GSCN) to distribute exosome injection and other biological products to ... Rica, Dominican Republic, Colombia, Argentina, Nicaragua, Panama, El Salvador, Venezuela, Peru, Ecuador, Paraguay, ...
(Date:2/10/2016)... , Feb. 10, 2016 NX Prenatal ... its proprietary NeXosome® technology for early warning of ... its most recent study by Dr. Thomas ... the Society for Maternal Fetal Medicine,s (SMFM) annual meeting ... 1-6 th , 2016.  The presentation reported initial ...
(Date:2/10/2016)... -- Matchbook, Inc., a company specializing in procurement and ... today the appointment of Jim Shuman ... 25 years of experience in supply chain, logistics ... decades in executive level roles as the SVP ... most recently headed global logistics and procurement at ...
Breaking Biology Technology:
(Date:2/3/2016)... February 4, 2016 --> --> ... 1,351.5 M (105.0), up 1,187% compared with fourth quarter of 2014. ... SEK 517.6 M (loss: 30.0). Earnings per share increased to ... SEK 537.4 M (neg: 74.7). , --> ... amounted to SEK 2,900.5 M (233.6), up 1,142% compared with 2014. ...
(Date:2/3/2016)... , Feb. 3, 2016 Vigilant Solutions announces ... Department in Missouri solved two ... reader (LPR) data from Vigilant Solutions. Brian ... in which the victim was walking out of a convenience store and witnessed ... next to his vehicle, striking his vehicle and leaving ...
(Date:2/2/2016)... 2016  BioMEMS devices deployed in hospitals ... medical screening and diagnostic applications, such as ... that facilitate and assure continuous monitoring without ... being bolstered through new opportunities offered by ... coupled with wireless connectivity and low power ...
Breaking Biology News(10 mins):